Monoclonal antibodies to C-reactive protein

• US 5,272,258 A
• Filed: 06/29/1989
• Issued: 12/21/1993
• Est. Priority Date: 06/29/1989
• Status: Expired due to Fees

• Current Assignee: Rush-Presbyterian St Luke's Medical Center Incorporated (Rush University)
• Original Assignee: Rush-Presbyterian St Luke's Medical Center Incorporated (Rush University)
• Inventors: Gewurz, Henry, Siegel, Joan N., Potempa, Lawrence A.
• Primary Examiner(s): Chan, Christina
• Assistant Examiner(s): Loring, Susan A.
• Application Number:
  US07/374,166
• Time in Patent Office: 1,636 Days
• Field of Search: 435/7, 435/240.27, 435/7.1, 435/7.2, 530/380, 530/387, 530/388.25
• US Class Current: 530/388.25
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons

Abstract

The invention comprises monoclonal antibodies reactive with native C-reactive protein (CRP) and modified CRP having the specificities described herein. The invention also comprises the hybridomas used to produce these antibodies. The antibodies may be used to detect or quantitate native CRP and modified CRP, and kits for performing such assays are part of the invention.

Claims

1. A monoclonal antibody which binds to C-reactive protein (CRP) and which has the following specificities:

a) reacts with native human CRP;

b) does not react with modified human CRP;

c) does not react with intact human CRP subunit;

d) does not react with fragment A of human CRP;

e) does not react with fragment B of human CRP;

f) does not react with CRP peptides 1 (residues 23-30 of human CRP), 2 (residues 109-123 of human CRP), 3 (residues 137-152 of human CRP) or 4 (residues 199-206 of human CRP);

g) does not react with serum amyloid P component;

h) recognizes a calcium-dependent epitope on native human CRP; and

i) its reactivity with native human CRP is not inhibited by phosphorylcholine.

8. A hybridoma capable of producing a monoclonal antibody according to claim 1.

9. An immunoassay for detecting or quantifying native C-reactive protein (CRP) comprising contacting a sample containing native CRP with a monoclonal antibody according to claim 1.

11. A kit for performing an immunoassay for native C-reactive protein comprising a container of a monoclonal antibody according to claim 1.

2. A monoclonal antibody which binds to C-reactive protein (CRP) and which has the following specificities:

a) reacts with native human CRP;

b) reacts with modified human CRP;

c) reacts with intact human CRP subunit;

d) does not react with fragment A of human CRP;

e) does not react with fragment B of human CRP;

f) recognizes a calcium-independent epitope on native human CRP;

g) its reactivity with native human CRP is not inhibited by phosphorylcholine;

h) does not react with CRP peptides 1 (residues 23-30 of human CRP), 2 (residues 109-123 of human CRP), 3 (residues 137-152 of human CRP) or 4 (residues 199-206 of human CRP); and

i) does not react with serum amyloid P component;

the monoclonal antibody having been produced by immunizing an animal with an immunogen selected from the group consisting of native human CRP, modified human CRP and the combination of modified human CRP and modified rabbit CRP.

13. A hybridoma capable of producing a monoclonal antibody according to claim 2.

15. An immunoassay for detecting or quantifying native C-reactive protein (CRP) or modified CRP comprising contacting a sample containing native or modified CRP with a monoclonal antibody according to claim 2.

3. A monoclonal antibody which binds to C-reactive protein (CRP) and which has the following specificities:

a) does not react with native human CRP;

b) reacts with modified human CRP;

c) reacts with intact human CRP subunit;

d) reacts with fragment A of human CRP;

e) does not react with fragment B of human CRP;

f) does not react with CRP peptides 1 (residues 23-30 of human CRP), 2 (residues 109-123 of human CRP), 3 (residues 137-152 of human CRP) or 4 (residues 199-206 of human CRP);

g) is not able to bind fluid phase native human CRP in the presence of absence of calcium; and

h) does not react with serum amyloid P component.

4. A monoclonal antibody according to claim 3 which has the further specificity:

i) reacts with modified rabbit CRP.

6. A monoclonal antibody according to claim 10 which has the further specificity:

i) reacts with modified rabbit CRP.

10. An immunoassay for detecting or quantifying modified C-reactive protein (CRP) comprising contacting a sample containing modified CRP with a monoclonal antibody according to any one of claims 3-7.

12. A kit for performing an immunoassay for modified C-reactive protein comprising a container of a monoclonal antibody according to any one of claims 3-7.

14. A hybridoma capable of producing a monoclonal antibody according to any one of claims 3-7.

16. A kit for performing an immunoassay for native C-reactive protein (CRP) or modified CRP comprising a container of monoclonal antibody according to claim 3.

5. A monoclonal antibody which binds to C-reactive protein (CRP) and which has the following specificities:

a) does not react with native human CRP;

b) reacts with modified human CRP;

c) reacts with intact human CRP subunit;

d) does not react with fragment A of human CRP;

e) reacts with fragment B of human CRP;

f) does not react with CRP peptides 1 (residues 23-30 of human CRP), 2 (residues 109-123 of human CRP), or 3 (residues 137-152 of human CRP);

g) is not able to bind fluid phase native human CRP in the presence of absence of calcium; and

h) does not react with serum amyloid P component.

7. A monoclonal antibody according to claim 5 which has the further specificity that it reacts with CRP peptide 4 (residues 199-206 of human CRP).